What is the role of (PEG)-interferon (IFN) in hepatitis C treatment in resource-limited settings?

Updated: Oct 07, 2019
  • Author: Vinod K Dhawan, MD, FACP, FRCPC, FIDSA; Chief Editor: BS Anand, MD  more...
  • Print

With the availability of newer directly acting agents (DAAs), and due to the poor safety profile of PEG-IFN, PEG-IFN is no longer recommended in combination regimens. However, in resource-limited settings, PEG-IFN alfa-2a continues to have a role in the management of acute and chronic HCV, as well as in those with end-stage renal disease and individuals who don't have access to or who are not candidates for DAA therapy. [99]

Ribavirin continues to be used in combination with sofosbuvir alone or other combinations.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!